Welcome to our dedicated page for Fulgent Genetics SEC filings (Ticker: FLGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Fulgent Genetics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Fulgent Genetics's regulatory disclosures and financial reporting.
Fulgent Genetics filed an 8-K to share updated clinical data for its cancer drug candidate FID-007. The company presented preliminary Phase 2 results at the ASCO 2026 Annual Meeting in a rapid oral abstract session focused on head and neck cancer.
The open-label, randomized Phase 2 study evaluates two dosing regimens of FID-007 combined with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after PD-1–based immunotherapy. As of the April 16, 2026 data cutoff, investigators reported meaningful clinical activity and a manageable safety profile.
According to a principal investigator, the combination produced an objective response rate of 61.9%, median progression-free survival of 6.7 months, median duration of response of 7.4 months, and one-year overall survival of 63.4%. A Phase 3 study of FID-007 is planned, and the ASCO presentation slides are being made available on Fulgent’s investor relations website.
Fulgent Genetics, Inc. President and COO Jian Xie reported an open-market sale of 1,201 shares of common stock on May 27, 2026 at a weighted-average price of $17.60 per share. The shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024.
Following the sale, Xie directly holds 369,751 shares of Fulgent Genetics common stock. An additional 220,816 shares are held indirectly by The Hsieh Family Dynasty Trust, where Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported a routine tax-related share disposition. On May 26, 2026, 1,168 shares of common stock were withheld to cover tax obligations arising from the vesting of restricted stock units granted on February 26, 2024. After this withholding, Kim directly holds 364,632 common shares.
Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported an open-market sale of common stock. On May 27, 2026, he sold 945 shares at a weighted-average price of $17.60 per share to satisfy tax withholding obligations from vested restricted stock units. After this transaction, Gao directly held 992,062 shares of Fulgent Genetics common stock, so the sale represents only a small fraction of his overall stake.
Fulgent Genetics, Inc. insider Ming Hsieh filed Amendment No. 5 to update his ownership in the company’s common stock. He beneficially owns 8,872,539 shares, representing 32.26% of the 27,493,435 shares outstanding as of May 22, 2026. The Ming Hsieh Trust beneficially owns 7,895,115 shares, or 28.72% of the class.
Since the prior amendment, Hsieh acquired additional shares solely through vesting of equity awards; on May 26, 2026, 5,496 RSU shares vested, with 2,949 shares withheld for taxes, and no cash consideration was paid. A total of 1,000,000 trust shares are pledged under a pre-paid forward arrangement and 5,760,733 trust shares secure a credit facility, so the lender may dispose of these if there is a default. Hsieh indicates he holds the stake for general investment purposes but may increase or decrease his holdings over time.
Fulgent Genetics, Inc. director and Chief Executive Officer Ming Hsieh reported a routine tax withholding event related to equity compensation. Upon vesting of restricted stock units granted on February 26, 2024, 2,949 shares of common stock were withheld at $17.67 per share to satisfy tax obligations, leaving him with 897,685 directly held shares.
He also reports substantial indirect holdings, including shares held by The Ming Hsieh Trust, the Dynasty Trust, a Uniform Transfers to Minor Act account, and an immediate family member in the same household, with individual positions such as 7,895,115 shares and 220,816 shares held via trusts.
Fulgent Genetics reported interim Phase 2 results for its cancer drug candidate FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma. The data come from an open-label, randomized study presented in a full abstract at ASCO 2026.
Among 42 efficacy-evaluable patients, the combination showed an objective response rate of 60%, with median progression-free survival of 7.2 months across two dosing arms. Median duration of response was 7.4 months, and over half of responders were still responding at the data cut-off of December 20, 2025.
The safety profile was described as favorable overall, with most treatment-related side effects in grades 1–2, though grade 3–4 events such as neutropenia, anemia, leukopenia and rash occurred, and there was one grade 5 treatment-related pneumonia. Overall survival data remain immature. The abstract is available on ASCO’s site, with final presentation slides to follow on June 1, 2026.
Fulgent Genetics director Michael Nohaile reported new equity awards. He received 5,558 shares of common stock as a grant, bringing his direct holdings to 24,578 shares. He was also granted options on 8,426 shares at an exercise price of $16.19 per share, expiring on May 13, 2036.
The 5,558 restricted stock units and the 8,426 options both vest over four years. One quarter vest 12 months after May 14, 2026, and the remainder vest in equal quarterly installments over the following 36 months, contingent on continued service with the company.
Dong Linda reported acquisition or exercise transactions in this Form 4 filing.
Fulgent Genetics director Linda Dong reported receiving 11,117 shares of Common Stock as a grant of restricted stock units at no cash cost. The award vests over four years, with 1/4 vesting 12 months after May 14, 2026 and the rest quarterly, leaving her with 38,758 directly held shares after the grant.
GROVES REGINA E reported acquisition or exercise transactions in this Form 4 filing.
Fulgent Genetics director Regina E. Groves received a grant of 11,117 shares of common stock in the form of restricted stock units. These units were awarded at no cash cost per share and increased her direct holdings to 28,099 shares after the transaction.
The restricted stock units vest over four years. One quarter of the shares vest 12 months after May 14, 2026, and the remaining three quarters vest in equal 1/16 portions at the end of every three-month period over the following 36 months, subject to her continued service with the company.